ASH 2020: Dr. Anthony Mato on LOXO-305 A Next Generation Highly Selective Non-Covalent BTK inhibitor.
During ASH 2020, Dr. Anthony Mato discussed LOXO-305, a new generation reversible BTKi (Bruton Tyrosine Kinase inhibitor). Early data from the BRUIN trial suggest that LOXO-305 is a promising new treatment option for CLL patients who have relapsed or become refractory to other BTKis.